{"title":"The Long-Term Effects of Pessary Treatment on Quality of Life, Symptoms, Sexual Function, and the Urinary System in Women with Pelvic Organ Prolapse.","authors":"Ozgen Nahya Ozdogar, Ibrahim Egemen Ertas","doi":"10.1007/s00192-025-06291-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>Although pessary treatment is widely used to treat pelvic organ prolapse (POP), there is currently no clear information on its impact on long-term quality of life. The aim of this study was to examine the effects of pessary treatment on quality of life (QoL), symptoms, sexual function, and the urinary system in women with POP.</p><p><strong>Methods: </strong>Patients who presented to our clinic due to POP and were treated with a pessary were evaluated. To examine the effects of pessary treatment on QoL, the urinary system, and sexual function, validated questionnaires, including the Pelvic Floor Distress Inventory-20 (PFDI-20), the Pelvic Floor Impact Questionnaire (PFIQ), and the Female Sexual Function Index (FSFI), were completed by those who continued to receive pessary treatment. The patients' gynecological examinations were performed.</p><p><strong>Results: </strong>Seventy patients were enrolled in the study. Four patients died owing to systemic comorbidities. Among the remaining patients, 12 discontinued pessary use (mean duration 27.36 months), while 54 continued the treatment (mean duration 25.43 months). The pessary size, total vaginal length (TVL), and genital hiatus (GH) of women with POP who discontinued treatment were greater than those who continued treatment. Previous gynecological operations and increased TVL were effective predictors for discontinuation of treatment. The total score and subheadings of the PFDI-20; PFIQ total score and subheadings, with the exception of the Colorectal-Anal Impact Questionnaire (CRAIQ-7); and FSFI scores improved after pessary treatment. Among patients who discontinued treatment, pain was the most common reason (41.6%).</p><p><strong>Conclusions: </strong>Pessary treatment was associated with improvements in pelvic floor-related quality of life and sexual function; however, pain emerged as the primary reason for treatment discontinuation.</p>","PeriodicalId":14355,"journal":{"name":"International Urogynecology Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urogynecology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00192-025-06291-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and hypothesis: Although pessary treatment is widely used to treat pelvic organ prolapse (POP), there is currently no clear information on its impact on long-term quality of life. The aim of this study was to examine the effects of pessary treatment on quality of life (QoL), symptoms, sexual function, and the urinary system in women with POP.
Methods: Patients who presented to our clinic due to POP and were treated with a pessary were evaluated. To examine the effects of pessary treatment on QoL, the urinary system, and sexual function, validated questionnaires, including the Pelvic Floor Distress Inventory-20 (PFDI-20), the Pelvic Floor Impact Questionnaire (PFIQ), and the Female Sexual Function Index (FSFI), were completed by those who continued to receive pessary treatment. The patients' gynecological examinations were performed.
Results: Seventy patients were enrolled in the study. Four patients died owing to systemic comorbidities. Among the remaining patients, 12 discontinued pessary use (mean duration 27.36 months), while 54 continued the treatment (mean duration 25.43 months). The pessary size, total vaginal length (TVL), and genital hiatus (GH) of women with POP who discontinued treatment were greater than those who continued treatment. Previous gynecological operations and increased TVL were effective predictors for discontinuation of treatment. The total score and subheadings of the PFDI-20; PFIQ total score and subheadings, with the exception of the Colorectal-Anal Impact Questionnaire (CRAIQ-7); and FSFI scores improved after pessary treatment. Among patients who discontinued treatment, pain was the most common reason (41.6%).
Conclusions: Pessary treatment was associated with improvements in pelvic floor-related quality of life and sexual function; however, pain emerged as the primary reason for treatment discontinuation.
期刊介绍:
The International Urogynecology Journal is the official journal of the International Urogynecological Association (IUGA).The International Urogynecology Journal has evolved in response to a perceived need amongst the clinicians, scientists, and researchers active in the field of urogynecology and pelvic floor disorders. Gynecologists, urologists, physiotherapists, nurses and basic scientists require regular means of communication within this field of pelvic floor dysfunction to express new ideas and research, and to review clinical practice in the diagnosis and treatment of women with disorders of the pelvic floor. This Journal has adopted the peer review process for all original contributions and will maintain high standards with regard to the research published therein. The clinical approach to urogynecology and pelvic floor disorders will be emphasized with each issue containing clinically relevant material that will be immediately applicable for clinical medicine. This publication covers all aspects of the field in an interdisciplinary fashion